Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
| Brand name | CARVEDILOL |
| Generic name | CARVEDILOL |
| Active ingredient(s) | CARVEDILOL |
| Distributed by / for | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430 |
| NDC | 68462-163-01 |
| Full product label | Carvedilol Tablets USP 6.25 mg, a.)100-count bottle (NDC 68462-163-01), b.) 500-count bottle (NDC 68462-163-05) Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | U.S. Nationwide |
| Quantity | [100 Tablet Bottles] 90,000 bottles; [500 Tablet Bottles] 324,288 bottles |
| Recall initiated | 2025-02-28 |
| Report date | 2025-06-04 |
| Recall completed | — |
| Recall number | D-0449-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗